Sarah M. McLeod

Statistics

Publications

Citations

H-Index

Active since

1998

Affiliations

Entasis Therapeutics (United States)(Current)

AstraZeneca (United States)

University of California, Los Angeles

AstraZeneca (United Kingdom)

Tufts University

Sarah M. McLeod is an author at Entasis Therapeutics (United States) specializing in life sciences, antibiotic resistance, and antimicrobial resistance.

ORCID

Publications per year

1998–2024

Publications

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 271 citations

Life Sciences, Infectious Diseases, Microbiology +16

Mechanism of Chromosome Compaction and Looping by the Escherichia coli Nucleoid Protein Fis

Dunja Skoko, Daniel Yoo, Hua Bai et al. · Journal of Molecular Biology · 2006 · 149 citations · Full text

Life Sciences, Microbiology, Molecular Biology +14

Rational design of a new antibiotic class for drug-resistant infections

Thomas F. Durand-Réville, Alita A. Miller, John P. O’Donnell et al. · Nature · 2021 · 140 citations

Life Sciences, Infectious Diseases, Medicinal Chemistry +16

Control of transcription by nucleoid proteins

Sarah M. McLeod, Reid C. Johnson · Current Opinion in Microbiology · 2001 · 118 citations

Life Sciences, Cell Biology, Molecular Biology +12

Novel Antibacterial Targets and Compounds Revealed by a High-Throughput Cell Wall Reporter Assay

Asha S. Nayar, Thomas J. Dougherty, Keith Ferguson et al. · Journal of Bacteriology · 2015 · 110 citations · Full text

Life Sciences, Microbiology, Antimicrobial Pharmacology +10

1–5 of 35